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Abstract  
Introduction: IgE-mediated food allergy (FA) has been emerging as a public health priority. It is a potentially 
life-threatening condition with negative impact on the quality of life of patients and their family and its 
prevalence is increasing in westernized countries in the recent two decades.   
The current standard approach to FA consists of the strict avoidance of the triggering food. However, an 
elimination diet may be difficult and frustrating, above all for those foods (e.g. milk and egg) that are 
pivotal in the common diet.  
Oral immunotherapy (OIT) may increase the amount of food that the patient can intake without reaction, 
and reduce the risk of potential life-threatening allergic reactions. It is currently considered the most 
promising treatment for FA. However, many gaps are still unsolved.  
Areas covered: The aim of this review is to shed light on the current evidence and the main needs in OIT in 
order to stimulate the development of longitudinal, prospective, well-designed studies with the final goal of 
a “precision medicine”.   
Expert Commentary: Clinical trials for OIT conducted so far are extremely heterogeneous. The aim in the 
near future is to identify the most suitable candidates to OIT and algorithms for treatments tailored on 
well-characterized subpopulations of patients.  
Key words: children, food allergy, mechanism of action, novelty, oral immunotherapy, precision medicine, 
quality of life, management     
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1. The previous view for treatment of food allergy 
IgE-mediated food allergy (FA) is an emerging public health priority. It is a major cause of life-threatening 
hypersensitivity reactions [1,2] and its incidence has increased significantly over the past two decades. It is 
estimated FA affects around 6–8 % of children and 2–3 % of adults in westernized countries. [1,3] 
Moreover, FA may negatively impact the quality of life (QoL) of patients and their family, since anxiety, fear 
of accidental exposures, requiring changes in dietary habits and social interactions. [4, 5]  
The natural history of the disease is influenced by the food involved. The majority of children with allergy to 
cow’s milk (CM), hen’s egg (HE), soy and wheat spontaneously overgrow their allergies over time. [6-11] 
Conversely, less than 20% of peanut or tree nut allergic patients develop naturally tolerance to these foods. 
[12, 13] The latter are responsible for the majority of fatal or near-fatal food allergic reactions. [14, 15]  
The traditional approach to FA lies on the strict avoidance of the triggering food and keeping as rescue 
medications (including epinephrine, corticosteroids, and antihistamines) readily available in the event of an 
allergic reaction occurs. [**16, 17] However, an elimination diet represents often an unrealistic therapeutic 
option for several reasons. It is difficult and frustrating in patients with persistent FA, above all for those 
foods (such as CM and HE) that are pivotal in the common diet and, therefore, ubiquitous in store-bought 
foods, and in home and restaurant recipes. [18] Nothwithstanding, despite efforts to comply with this diet, 
accidental exposures leading to adverse reactions are frequent. [19] Allergens can be hidden in 
unsuspecting foods, labeling is often misleading, safe food can be contaminated when served with a dirty 
utensil and cross-reacting allergens may be present in other alimentary sources. [19] 
2. The current view: the active treatment for IgE mediated food allergy 
The above mentioned limitations of the food avoidance concurrently with a better understanding in the 
patho-mechanisms underlying FA have stimulated an increasing interest towards an active treatment of the 
disease. Since the first case described in 1908 [20], oral immunotherapy (OIT) has gained momentum as a 
potential curative treatment in patients with persistent FA. [**21] Other routes of administration, including 
the sublingual (SLIT) and epicutaneous (EPIT) ones are under investigation. However, head to head studies 
comparing OIT versus SLIT show a better effectiveness of the oral route of administration. [**16, **21] 
More data about EPIT are currently awaited before it can be recommended. [**16, **21] 
OIT implies the reiterated administration of the culprit food. Most protocols consist of three successive 
phases, respectively: initial escalation, up-dosing, and maintenance. Usually, the initial dose escalation 
starts with incremental administration of small amounts of food allergen, below the threshold of reactivity, 
usually over 1–2 days. The up-dosing starts with daily ingestion of the highest dose tolerated during 
escalation phase; then, doses increased usually weekly or biweekly until the maintenance dose is reached. 
In the maintenance phase, patients consume the food regularly (often daily) for months or years. However, 
OIT protocols are widely heterogeneous among studies. There are some rush protocols and slow up-dosing 
regimens with or without an initial dose escalation day. Unfortunately, the heterogeneity in the 
populations under study, methods employed and outcomes studied made it challenging to interpret the 
evidence among studies. [**21]  
OIT is a potential curative treatment for FA.  It may increase the amount of food that the patient can intake 
without reaction, and reduce the risk of potential life-threatening allergic reactions. [**21] There is strong 
evidence for the effectiveness during treatment, also referred as “desensitization” [**21]; this is defined as 
the ability to safely assume the food-antigen, while consuming the OIT doses regularly. However, a more 
desirable goal of FA-AIT lies on the effectiveness after discontinuing the treatment, also known as 
“tolerance” or “post desensitization effectiveness”, and referred to the absence of symptoms after 
ingestion of a normal serving of the culprit food despite a period of absence of exposure and remains still 
one of the major issues to be clarified. [**21]   
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2.1  Current gaps 
OIT constitues currently the most promising treatment for FA, as able to modulate the specific immune 
response against the culprit allergen. However, many gaps remain still unsolved (Table 1). For istance, OIT 
is logistically demanding and time-consuming and most patients are affected by side effects though often 
mild. Furthermore, the patho-mechanisms are overall not well-known yet. There is still a long way to go to 
determine the extent to which the mechanisms underlying “desensitization” versus “long-term tolerance” 
are similar or different and to develop tests that can reliably determine the immune status of food allergic 
subjects. Some of the main gaps are discussed below to stimulate longitudinal, prospective, well-designed 
studies able to reach the final goal of a “precision medicine” tailored on each single patient suffering from 
FA.   
2.1.1 Standardized products and vehicles 
First of all, the availability of standard products results urgent. In order to provide both a reliable diagnosis 
of clinical allergy (eg. IgE assays, skin prick testing and oral food challenge) and an effective treatment (OIT), 
the availability of medicinal products plays a pivotal role. To our best knowledge, there are no currently 
authorized medicinal products in the field of FA. However, some phase 3 clinical trial are ongoing [22] and 
some preliminary results from the respective Phase 2 studies have been already provided [23] The 
constallations of products so far used in the different trials are enormously heterogeneous. Typically, the  
natural-raw form is used [24]. However, the use of different type of processed foods could be an 
alternative treatment. [25] The presence of the allergens can vary inside a food (e.g. egg white and yolk) 
but also the duration and type of processing (such as homogenization, dry and most thermal processing, 
fermentation, hydrolysis, irradiation) and the food matrix may influence the allergenic potential and, 
therefore, the ability of foods to elicit allergic reactions.[26] For instance, the majority (50–85%) of egg 
allergic patients are tolerant to baked egg products as an extensive heating diminishes the allergenicity of 
egg white proteins [27]; the allergenicity of peanut proteins could be reduced by boiling and, on the 
contrary, increased by roasting. [28] Furthermore, most studies have focused on peanut, milk, or egg. Other 
foods should be investigated. 
2.1.2 Standardized protocols 
The landscape of OIT protocols used in OIT studies is widely heterogeneous. First, the study design may be 
different (open label versus double blinded, placebo-controlled; randomized controlled trials versus 
controlled clinical trial; multi-site versus single-site; and so on). Inclusion and exclusion criteria for 
enrollment vary as well. Some studies included only patients with severe FA [30], and others excluded them 
[31]. Furthermore, there is lack of evidence in adults. Most studies have been conducted in pediatric 
population [31] and others in mixed population (children plus adults, with prevalence of children) [**21]. 
As the natural history of allergies differs among the foods [6-11], it should be useful to perform subgroup 
analyses based on different ranges of age in childhood in order to better understand the best timing/time-
window to start OIT for each culprit food. However, most studies pool data from wide age-range and 
subgroup analyses are not feasible. [**21] 
Duration and dosing in each OIT phase differ among the studies: some regimens have a “rush” phase [32], 
others a slower schedule with smaller increasing doses and/or interval-length in between. [31] The target 
maintenance dose ranges widely also for the same food. [34-35] This variability should be considered when 
the results are compared. 
There is evidence that low amount of food used as maintenance doses are able to maintain full 
desensitization. [36, 37] However, among the main needs still unanswered, to establish validated protocols 
with optimal dose of the culprit food allergen to be used for maintenance, the length of the maintenance 
period, and the sustainability of the desensitization process remain still of high priority. 
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2.1.3 Improvement of post-discontinuation treatment effectiveness    
The assessment of standardized protocols relates strictly to the requirements to define clinically relevant 
outcomes of effectiveness. It is yet unclear which duration and frequency of ingestion of the allergic food(s) 
are required to maintain desensitization and we are lacking criteria with which to evaluate and diagnose 
permanent tolerance, too. To this regard, it is important to distinguish the term ‘oral tolerance’ from 
‘sustained unresponsiveness’. In both, there is lack of reactivity to ad libitum allergen ingestion. The first 
implies lifelong tolerance, whereas the second refers to an unknown duration of tolerance, usually 
achieved as a result of a treatment intervention (i.e. immunotherapy) [37]. A few studies evaluated the 
post-discontinuation treatment effectiveness  and furthermore by different approaches as both the 
duration of maintenance and the abstinence period (2 weeks to few months), sometimes within the same 
trial. [24, 25, 29, , 38-45] Re-challenge after varying periods of avoidance has shown rates of non-reactivity 
to a food challenge ranging from 18%-78% and most subjects still maintained a state of desensitization to a 
threshold level higher than their screening challenge. [24, 25, 29, , 38-45] Validated protocols with optimal 
dosing and duration of therapy are urgently required in order to assess the acquisition of the ability to 
safely consume a normal serving of foods containing the trigger allergen despite a period of absence of 
exposure. 
2.1.4 Mechanisms of action of OIT and markers of response 
There is still a long way to go to determine the extent to which the mechanisms underlying ‘desensitization’ 
vs. ‘sustained unresponsiveness’ are similar or different and to develop tests that can reliably determine 
the immune status of subjects suffering from FA. Similarly to the mechanisms of action in allergen specific 
immunotherapy explored in allergic rhinitis and insect venom allergy, the protection from reactions in the 
early stages of immunotherapy are due to decreased activation of mast cells and basophils, which has been 
seen as early as in the first 3-4 months of OIT. [45- 48] In addition, many other cell types might contribute 
to early immunotherapy responses but this needs further investigations. The induction of peripheral T cell 
tolerance is a pivotal step induced by immunotherapy, and in different models various changes in antigen 
specific T cell populations correlated with tolerance, including increased T-regulatory cells, decreased Th2 
cells, and increased anergic T cells. [49,50] The proportion of antigen-specific T cell subsets and the change 
in the dominant subset may skew towards allergy vs. tolerance. [51] OIT can induce changes in 
immunoglobulin subsets. Patients undergoing peanut OIT for a median of 41 months had serum increased 
levels of peanut-specific IgG4 with de novo specificities associated with reduced serum levels of peanut-
specific IgE. [52] Although increasing evidence supports a role for antigen-specific IgG4 in directly inducing 
tolerance, IgG4 levels may also correlate with other mechanisms promoting tolerance. 
There is still a long way to go to determine the extent to which the mechanisms underlying ‘desensitization’ 
vs. ‘sustained unresponsiveness’ are similar or different and to develop tests that can reliably determine 
the immune status of food allergic subjects.  
 
2.1.5 Impact on quality of life and cost-effectiveness   
Food allergy is associated with a negative impact on the quality of life [4, 5,52] and the total annual 
economic burden of patients and their families. [4, 5, 53, 54] On the other side, though a promising therapy 
for FA, OIT can be linked to anxiety. [**21] OIT is time-consuming, logistically demanding, and most 
patients are affected by side effects, though usually mild. [**21] However, OIT could possibly lead to 
significant and long-term improvements in patients and their respective caregivers. [**21, 34, 54, 55] This 
should be furtherly investigated as well as the cost-effectiveness impact of OIT. [**21] In addition, OIT 
represents the emerging reality that provides both hope and optimism to patients burdened by persistent 
food allergy. 
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3. Indications and patients’selection 
OIT is potentially indicated for patients with evidence of persistent FA and in whom avoidance measures 
are ineffective, undesirable or cause severe limitations to their quality of life. In Figure 1, the procedural 
algorithm for the management of IgE mediated food allergy is represented. Before initiating OIT, a proper 
diagnosis is mandatory. It is based on a recent, clear clinical history of an acute reaction(s) after 
consumption of the triggering food and evidence of allergic sensitization towards the latter by skin prick 
tets and/or sIgE. [**16] Whether the diagnosis is unclear, oral food challenge is required; and the baseline 
reaction threshold may be used to establish the efficacy of OIT in individual patients. [**21]  
OIT is logistically- and time- demanding, based on immunological mechanisms and adverse events 
(including anaphylaxis) may occur during the treatment. Therefore, it is crucial that OIT is performed only in 
centres with professional training in FA care and expertise, competencies and full resuscitation facilities to 
safely deliver this treatment and manage any complications. Only patients who, alongside their families, 
understand the aim of the treatment and its risks, and who are motivated and adherent may be cadidable 
to OIT. 
Concerning the patient’s age, several issues should be considered. There is lack of evidence for adults. Most 
of the studies enrolled pediatric or mixed populations with heterogeneous age and linical presentations. 
[**21] Some studies have included infants and pre-school children who have tolerated FA-AIT safely. 
[29,30] However, young children might be not able to report early symptoms of allergic reactions and in 
children with FA -particularly to CM, HE, wheat and soy- is highly likely the development of spontaneous 
tolerance. [7-11,32,56] Keeping in mind these considerations, it might be more appropriate to wait for the 
natural acquisition of spontaneous tolerance before starting AIT for these allergens. [7-11,32,56] The right 
time to commence may be around 4-5 years of age, but this should be decided on an individual basis. 
4. Contraindications and Safety 
The Latin locution “Primum non nocere” (i.e. "first, to do no harm") is still an axiom central in the medical 
deontology. Contraindications should be careful evaluated before commencing the treatment. [**21]  As 
OIT is a logistically demanding tretmant affected by the risk of adverse event, a poor compliance represents 
an absolute contraindication. The latter inclu e also the following: uncontrolled or severe asthma; active 
malignant neoplasia(s); active systemic, autoimmune disorders; active eosinophilic esophagitis (EoE) or 
other gastrointestinal eosinophilic disorders; and initiation during pregnancy. Safety is a pivotal issue in any 
treatment [57-59]. Furthermore, in OIT, it is particularly important, as children are typically involved and 
potential adverse events are mostly immediate onset, food-induced IgE-mediated reactions, which can lead 
to anaphylaxis. Thus far, no fatality has been reported in literature, but systemic reactions are consistently 
described as common. Another adverse reaction, whose potential onset should be monitored consists of 
eosinophilic esophagitis.  [60] An up-to-date meta-analysis conducted by the European Academy of Allergy 
and Immunology  (EAACI) estimates that patients in the OIT-active arm have a 9% higher risk of systemic 
reaction than those in the placebo groups (RR: 1.16, 95% CI 1.03 – 1.30).[**21] Converserly, the rate of 
adverse events (AEs) during OIT largely varies in published studies but mild AEs are predominant and only a 
few dropped out for this reason.[**21] Unfortunately, reporting, description and grading of AEs are 
heterogenous and imprecise, and this makes it difficult to compare the real occurrence and severity of 
specific type of AEs among studies [57]. This drawback also affects the identification of risk factors and their 
avoidance. However, some risk factors are well-known. They include exercise, infection, and menses which 
may increase the risk of reactions [40], especially during the maintenance phase(s) of OIT, when patients 
continue treatment at home. Notwithstanding, in OIT studies most adverse reactions have been reported in 
the absence of these risk factors. [**21] Also some biological and clinical markers have been evaluated. 
Patients with higher serum specific IgE levels (>8.85 kU/L to ovomucoid in HE-OIT, and >50 kU/L to CM in 
CM-OIT), higher skin tests (>9 mm to milk in CM-OIT), low threshold of reactivity and/or severe reactions in 
the entry food challenge or upon accidental exposure, and underlying asthma seem to be at high risk for 
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repeated reactions and early FA-AIT failure.[58] However, the establishment of a common registry of 
systemic adverse events and further larger observational and controlled trials are awaited for a precise 
identification of biomarkers and predictors of severe AEs and, therefore, the necessity of safety measures 
(such as longer and slower up-dosing phase, premedication with H1-antihistamines, chromones, or even 
omalizumab).  
5. Administration regimen and Adherence 
Currently OIT is not standardized but instead tailored to individual patient with consideration of many 
factors  such as severity and type of culprit food, patient’s and family’s justification, age of subject who 
undergoes the treatment. Thus far, the use of fresh material or native food for OIT is adivisable to achieve 
both desensitization and post- desenzitazion effectiveness. Oral Immunotherapy and other forms of AIT for 
the active treatment of food allergy can be performed in specilized medical centers [**16]. Different 
schedules and up-dosing regimens were used in clinical trials: rush immnotherapy and slow updosing 
regimen. [61] Altogether, the amount of tolerated dose(s) of foods is marginally affected by the different 
regimens. [62] The need for daily dosing raises concern regarding patients’ adherence over long periods of 
time, as well as unintentional dosing interruption(s) due to illness, travel or family problems. Nowdays, it is 
seems that “ad libitum” consumption of known food allergens to maintain post- desensitization 
effectiveness does not appear to be required in all cases. Therefore, more flexible maintenance regimens 
are possible at least for children who have been successfully desensitized [63, 64]. These findings are of 
pivotal importance because twice weekly maintenance dosing wil represent an attractive approach for 
long- term food OIT contributing to OIT adherence [63,64]. Furtermore, recently have been shown that 
adherence to OIT was significantly higher in patients consuming 1200 mg of peanuts (76, 96.1%) vs those 
consuming 3000 mg (24/35, 72.2%), (P = .001). [65] 
 
6. Desensitization and post desensitization effectiveness 
OIT involves ingesting gradually increasing doses of allergenic food and represents the most effective  route 
of  administration to induce desensitization to foods, including milk, egg, and penut. Whether OIT can 
induce post- desensitization effectiveness is still controversial. [**16] Currently oral desensitization 
represents the first step toward a permanent tolerance or post- desensitization effectiveness. As with other 
kinds of immunotherapy (i.e for environmental allergenes) the duration of desensitization could be pivotal 
for achieving post- desensitization effectiveness. It is reasonable to think that in developed countries the 
almost continuous or frequent ingestion of foods -such as CM or HE- usually present in the diet, after the 
achievement of desensitization is per se easy to do by patients; thererefore, active specific immunotherapy 
might be permanently  successful for some food allergens, even without long periods of withdrawal. In 
other words, in good clinical practice for foods such as milk and egg, after the achievement of 
desensitization, the chance of friendly accompainying patient to post- desensitization effectiveness 
(tolerance) represents a possible therapeutical option. Of note, long enough trials with appropriate controls 
on post desensitization effectiveness are awaited. 
 
 
7. Adjunctive therapies to OIT  
In order to improve the effectiveness and the safety profile, a few novel therapeutic approaches are being 
assessed, most of them in pre-clinical or early clinical trials. In particular, omalizumab, the anti-IgE 
monoclonal antibody, represents currently the most promising adjunctive treatment. By binding the freely 
circulating human IgE but not mast cell- or basophil-bound IgE, it makes IgE unable to bind to its specific 
high affinity receptor (FceRI) on mast cells and basophils. Some studies have already shown that pre-
treatment with this expensive therapy could make safer OIT, preventing the systemic reactions while 
achieving the beneficial effects of desensitization. [*59-6166, 67] Furthermore, OIT is an allergen specific 
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therapy and, therefore, treating multiple allergies may represent a complex, long and expensive treatment. 
Theoretically, one such combined approach could be the best therapeutic option in patients with allergies 
to multiple foods and/or having failed a previous treatment with OIT alone [68]. Notwithstanding, further 
studies are waited to better clarify optimal doses and schedule of this combined treatment.  
Among adjuvants for FA-AIT, modified bacterial products are under investigation since bacteria are potent 
stimulants of Th1 immune responses. [69, 35] 
 
8. Expert commentary & five-year view 
IgE-mediated food allergy represents both a promising and an intriguing field of application for allergen 
immunotherapy, especially in the oral form. However, the procedure is time-consuming and not devoid of 
side effects, whereas we know that many children with cow’s milk allergy and hen’s egg allergy develop 
tolerance spontaneously and they can be easily managed with allergen avoidance. 
Currently, the use of fresh material or native foods is advisable to achieve the goal of desensitization. On 
the other hand a race to develop commercial treatment for food allergy is ongoing particularly for peanut 
allergy. Standardized vaccines of known potency are awaited. Currently studied therapies have some 
limitations such as variety of parameters included in the methods and heterogeneity in the protocols, and 
do not offer reassurance regarding long-term protection following discontinuation of treatment. 
Recently, the European Academy Allergy and Clinical Immunology (EAACI) published meta-analyses and 
guidelines for AIT for IgE-mediated food allergy. [**16, **21] Notwithstanding, gaps in practical 
management of AIT could be utilized for patients with persistent IgE-mediated food allergy in clinical 
centers with an extensive experience and in-depth knowledge of procedure(s) of AIT. 
The achievement of post desensitization effectiveness represents a desiderable goal of AIT. This is possible 
at least for children who have been successfully desensitized to CM. [63] In this context the post-
desensitization strategy and AIT for adult patients with food allergy are the areas of research that need 
progress. 
Hopefully, within the next few years clinicians will gain a better understanding of the utility of AIT, discover 
biomarkers predictive of favorable outcomes and carry on with strategies to improve the active treatment 
of IgE mediated food allergy (e.g. association with biologicals) in order to provide a ‘precision treatment’ 
tailored on the specific features of each patient. 
 
Key issues  
• Oral immunotherapy represents an active treatment for IgE-mediated food allergy.  
• The management of food allergy is related to the natural history of the disease. Most of chidren allergic 
to cow’s milk and hen’s egg overgrow their disease spontaneously. Therefore, for these allergens, OIT 
should be considered for children older than 4-5 years with persistent allergic symptoms.  
• Currently, the use of fresh materials or native foods is advisable. 
• OIT should be performed in selected medical centers and under strict medical supervision. 
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Table 1. Main current gaps in the evidence of FA-AIT  
 
Main gaps in the evidence of FA-AIT  
1. Standardized products  
2. Validated and shared protocols  
3. Definition of clinically relevant outcomes of effectiveness  
4. Improvement of post-discontinuation treatment effectiveness   
5. Safety profile 
6. Adjunctive treatment(s) 
7. Mechanisms of action 
8. FA-related quality of life  
9. Cost-effectiveness 
10. Identification of markers of response  
11. “Precision medicine”  
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